IRVINE, Calif.--(BUSINESS WIRE)--Sept. 11, 2006--Cortex Pharmaceuticals, Inc. (AMEX: COR) has submitted to the Food and Drug Administration (FDA) the Company’s complete response to each of the points raised by the FDA regarding certain toxicology issues on its lead AMPAKINE(R) compound, CX717. By its regulations, the FDA is required to respond within 30 days as to whether it will remove or maintain the clinical hold. Cortex has every confidence the FDA will meet the required timeframe.
